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Background: Development of an environmentally benign process for the synthesis of silver 
nanomaterials is an important aspect of current nanotechnology research. Among the 600   species 
of the genus Dioscorea, Dioscorea bulbifera has profound therapeutic applications due to its 
unique phytochemistry. In this paper, we report on the rapid synthesis of silver nanoparticles 
by reduction of aqueous Ag+ ions using D. bulbifera tuber extract.
Methods and results: Phytochemical analysis revealed that D. bulbifera tuber extract is 
rich in flavonoid, phenolics, reducing sugars, starch, diosgenin, ascorbic acid, and citric acid. 
The biosynthesis process was quite fast, and silver nanoparticles were formed within 5 hours. 
Ultraviolet-visible absorption spectroscopy, transmission electron microscopy, high-resolution 
transmission electron microscopy, energy dispersive spectroscopy, and x-ray diffraction con-
firmed reduction of the Ag+ ions. Varied morphology of the bioreduced silver nanoparticles 
included spheres, triangles, and hexagons. Optimization studies revealed that the maximum 
rate of synthesis could be achieved with 0.7 mM AgNO3 solution at 50°C in 5 hours. The 
resulting silver nanoparticles were found to possess potent antibacterial activity against both 
Gram-negative and Gram-positive bacteria. Beta-lactam (piperacillin) and macrolide (eryth-
romycin) antibiotics showed a 3.6-fold and 3-fold increase, respectively, in combination with 
silver nanoparticles selectively against multidrug-resistant Acinetobacter baumannii. Notable 
synergy was seen between silver nanoparticles and chloramphenicol or vancomycin against 
Pseudomonas aeruginosa, and was supported by a 4.9-fold and 4.2-fold increase in zone 
diameter, respectively. Similarly, we found a maximum 11.8-fold increase in zone diameter of 
streptomycin when combined with silver nanoparticles against E. coli, providing strong evidence 
for the synergistic action of a combination of antibiotics and silver nanoparticles.
Conclusion: This is the first report on the synthesis of silver nanoparticles using D. bulbifera 
tuber extract followed by an estimation of its synergistic potential for enhancement of the anti-
bacterial activity of broad spectrum antimicrobial agents.
Keywords: Dioscorea bulbifera tuber extract, silver nanoparticles, antimicrobial synergy
Introduction
Nanoparticles have received considerable attention in recent years due to their wide 
range of applications in the fields of catalysis, photonics, optoelectronics, biological 
tagging, pharmaceutical applications environmental pollution control, drug delivery 
systems, and material chemistry.1–3 Although there has been extensive research on the 
chemical synthesis of nanoparticles, these particles have several potential hazards, 
including carcinogenicity, genotoxicity, cytotoxicity, and general toxicity.4,5 There is a International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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need to develop clean, nontoxic, and ecofriendly procedures 
for synthesis and assembly of nanoparticles.4 Synthesis of 
metal nanoparticles is solely dependent on knowledge of 
micro-organisms and their behavior, which play a crucial 
role. Against this background, researchers have been   working 
extensively on extracellular and intracellular synthesis of 
metal nanoparticles using bacteria, fungi, yeasts, and many 
other biological sources.6–8 One of the major drawbacks to 
using microbes for bioreduction is the need to maintain asep-
tic conditions, which is not only labor-intensive but also very 
expensive in terms of industrial production costs. There are 
reports on the synthesis of nanoparticles using lemon grass 
and neem leaves.9,10 Leaf extracts have been used for synthesis 
of silver nanoparticles, which has highlighted the possibility 
of rapid synthesis and may also reduce the steps involved in 
downstream processing, thereby making the process more 
economical and cost-efficient.11–13 Sastry et al, Shankar et al, 
and Ankamwar et al have worked extensively on the biosyn-
thesis of metal nanoparticles from various plant sources.6,11,14 
They have reported on synthesis of nanoparticles having 
exotic shapes and morphologies.9 The spectacular success in 
this field has opened up the prospect of developing “green 
synthesis” methods for metal nanoparticles with tailor-made 
structural properties using benign starting materials. Silver 
has been used as a healing and antibacterial agent throughout 
the world for thousands of years.15 Its benefit over the use 
of antibiotics can be used as a powerful strategy to combat 
the increasing spread of multidrug resistance resulting from 
broad use of antibiotics. Therefore, the clinical efficacy of 
antibiotics has been compromised. Antibiotic resistance has 
become a serious problem threatening the health of human 
beings.16–20 Of all the inorganic antimicrobial agents, silver 
elements and nanoparticle compounds have been the most 
extensively tested. Sondi and Salopek-Sondi recently dem-
onstrated that silver (0) nanoparticles are quite effective 
antimicrobial agents against Escherichia coli.21 In addition, 
silver nanoparticles have excellent properties in terms of 
conformational entropy in polyvalent binding, which makes 
it easy for them to attach to flexible polymeric chains of 
antibiotics.22,23 Moreover, silver nanoparticles have well 
developed surface chemistry and chemical stability, and 
are of appropriate size. They are able to maintain a constant 
shape and size in solution. Thus, silver nanoparticles are 
a good choice as inorganic nanomaterials in combination 
with various classes of antibiotics for use against pathogenic 
micro-organisms.
Dioscorea bulbifera is unique among 600   species of the 
genus Dioscorea due to its species-specific phytochemistry, 
supporting its widespread application in   therapeutics.24 
D. bulbifera tuber extract is rich in polyphenolic compounds, 
especially flavonoids and catechin, which have contributed to 
its pronounced antioxidant and antidiabetic properties.25–27 In 
an earlier report, we reported synthesis of gold nanoparticles 
using D. bulbifera.28   However, to date, there are no reports on 
the synthesis of silver nanoparticles using D. bulbifera tuber 
extract. In view of this background, a detailed investigation 
is required into its potential for use in the synthesis of silver 
nanoparticles, along with characterization and application 
in therapeutics. Similarly, there are no reports including 
thorough evaluation of the role of silver nanoparticles in the 
enhancement of efficacy of a diverse group of antibiotics, 
ie, β-lactams, cephalosporins, aminoglycosides, rifamycins, 
glycopeptides, quinolones, tetracyclines, trimethoprim, car-
bapenems, cyclic peptides, and macrolides, against a wide 
group of Gram-positive and Gram-negative bacteria.
In this paper, we report for the first time the synthesis of 
silver nanoparticles by reduction of aqueous Ag+ ions with the 
assistance of D. bulbifera tuber extract. We have used tuber 
broth for the biogenic reduction of Ag+ ions. Our objective 
in this work was to reduce ionic silver to nanoparticles using 
a biomaterial that addresses two major factors, ie, the need 
for the biomaterial to be environmentally benign and produce 
no toxic industrial waste and for it to be cost-effective and 
easily produced. We also investigated the effects of reaction 
conditions, such as temperature and AgNO3 concentration, 
on the rate of synthesis of silver nanoparticles. We studied 
their antimicrobial effects at various concentrations against 
a wide range of Gram-negative and Gram-positive bacteria. 
Furthermore, we evaluated the silver nanoparticles in com-
bination with various groups of antibiotics for synergistic 
enhancement of antimicrobial activity against pathogenic 
bacteria. Herein, we present the first detailed study of the 
synergistic potential of biogenic silver nanoparticles in 
combination with 22 different antibiotics against 14 potent 
bacterial pathogens.
Materials and methods
Plant material and preparation of extract
D. bulbifera tubers were collected from the Western 
Ghats region in Maharashtra, India, chopped into thin 
slices, and dried for two days at room temperature. The 
tuber extract was prepared by putting 5 g of thoroughly 
washed and finely ground tuber powder into a 300 mL 
Erlenmeyer flask with 100 mL of sterile distilled water, 
boiling the mixture for 5 minutes, then decanting it. The 
extract obtained was filtered through Whatman No 1 filter International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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paper. The filtrate was collected and stored at 4°C for 
further use.
Phytochemical analysis
Total flavonoid content
A 0.5 mL sample of D. bulbifera tuber extract was mixed with 
0.5 mL of 2% AlCl3 in methanol and incubated for 10 minutes 
at room temperature. After exactly 10 minutes, absorbance 
was recorded at 368 nm. The total phenolic content was 
quantified from a standard quercetin curve.29
Total phenolic content
A 0.125 mL sample of D. bulbifera tuber extract was mixed 
with 0.5 mL of deionized water. Folin-Ciocalteau reagent 
0.125 mL was added and incubated for 5 minutes at room 
temperature followed by addition of 1.25 mL of 7% Na2CO3 
  solution. The volume was made up to 3 mL with distilled water 
followed by incubation for 90 minutes at room   temperature. 
Absorbance was recorded at 760 nm. Total flavonoid content 
was estimated from a standard gallic acid curve.30
starch content
Five grams of dry D. bulbifera tuber powder was repeatedly 
washed using 70% ethanol to remove sugars until the wash-
ings did not show color with an anthrone reagent. The residue 
was dried and boiled in 100 mL of distilled water to obtain 
D. bulbifera tuber extract without any sugars. A 1 mL sample 
of D. bulbifera tuber extract was evaporated to dryness and 
reconstituted in 60% perchloric acid. Thereafter, 4 mL of 
anthrone reagent was added, followed by boiling in a water 
bath for 8 minutes. The intensity of the dark green color was 
recorded at 630 nm, and the starch content was estimated by 
comparison with a standard glucose curve.31
Total reducing sugar
A 100 mL quantity of D. bulbifera tuber extract was made 
up to a volume of 1 mL using distilled water, and 1 mL of 
dinitrosalicylic reagent was added. The mixture was kept 
at 100°C for 5 minutes, and absorbance was recorded at 
540 nm. Total reducing sugar was quantified from a standard 
maltose curve.32
Diosgenin content
A 1 mL sample of D. bulbifera tuber extract was evaporated 
to dryness, and 5 mL of 60% perchloric acid was added to the 
dry residue and mixed thoroughly. Absorbance was recorded 
at 410 nm after 10 minutes, and the diosgenin content was 
determined from a standard diosgenin curve.33
Ascorbic acid content
A 2 mL sample of D. bulbifera tuber extract was evaporated 
to dryness, followed by reconstitution in oxalic acid 4%. 
The sample was then brominated and 1 mL of dinitrophe-
nyl hydrazine reagent was added, followed by two drops of 
10% thiourea. After mixing thoroughly, the tube was kept at 
37°C for 3 hours. The orange-red osazone crystals formed 
were dissolved in 7 mL of 80% sulfuric acid. Absorbance 
was measured at 540 nm. The content of ascorbic acid in 
the D. bulbifera tuber extract was quantified by comparison 
with a standard curve for ascorbic acid.34
citric acid content
A 1 mL quantity of D. bulbifera tuber extract was evaporated 
to dryness and reconstituted in 1 mL of 5% trichloroacetic 
acid. The tube was stoppered after dropwise addition of 
8 mL of anhydrous acetic anhydride, followed by incubation 
at 60°C for 10 minutes in a water bath. Thereafter, 1 mL of 
pyridine was added to each tube and restoppered, after which 
the tube was incubated at 60°C for 40 minutes. At the end 
of this period, the tube was transferred to an iced water bath 
for 5 minutes and absorbance was recorded at 420 nm. The 
total citric acid content was determined from a standard citric 
acid curve in the range of 10–400 µg/mL.35
synthesis of silver nanoparticles
Ag+ ions were reduced by addition of 5 mL of D. bulbifera 
tuber extract to 95 mL of 10–3 M aqueous AgNO3 solution. 
Reduction of the Ag+ ions was monitored by measuring the 
ultraviolet-visible spectrum of the solution at regular intervals 
on a spectrophotometer (SpectraMax M5, Molecular Devices 
Corporation, Sunnyvale, CA) operating at a resolution 
of 1 nm. The effects of temperature on the rate of synthesis 
and size of the prepared silver nanoparticles were studied by 
carrying out the reaction in a water bath at 4°C–50°C with 
reflux. The concentration of AgNO3 solution was also varied 
from 0.3 to 5 mM.
TeM, hrTeM, and dynamic light 
scattering measurements
The surface morphology and size of the bioreduced silver 
nanoparticles was determined using a transmission elec-
tron microscope (TEM, Tecnai 12 Cryo, FEI, Eindhoven, 
The Netherlands). The morphology and size of the silver 
nanoparticles were also characterized by a higher resolution 
transmission electron microscope (HRTEM, JEOL-JEM-
2100, Peabody, MA). Energy-dispersive spectra for the silver 
nanoparticles taken using an energy dispersive spectrometer International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
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equipped with a JEOL JSM 6360A analytical scanning 
electron microscope at an energy range 0–20 keV confirmed 
the synthesis of silver nanoparticles using D.   bulbifera 
tuber extract. The size of the particles in 3 mL of the reac-
tion mixture was analyzed using dynamic light scattering 
equipment (Zetasizer Nano-2590, Malvern Instruments Ltd, 
Worcestershire, UK) in a polystyrene cuvette.
X-ray diffraction measurements
Phase formation of the bioreduced nanoparticles was studied 
using x-ray diffraction. Diffraction data for thin thoroughly 
dried nanoparticle films on glass slides were recorded on an 
x-ray diffractometer (D8 Advanced, Brucker, Germany) with 
a Cu Kα (1.54 Å) source.
Fourier transform infrared spectroscopy
A dry nanoparticle powder was obtained in the following 
manner. Silver nanoparticles synthesized after 5 hours of 
reaction of 1 mM AgNO3 solution with  D. bulbifera tuber 
extract  were centrifuged at 10,000 rpm for 15 minutes at 
room temperature, after which the pellet was redispersed 
in sterile distilled water. The process of centrifugation and 
redispersion in sterile distilled water was repeated three 
times to ensure better separation of free entities from the 
nanoparticles. The purified pellet was then dried and sub-
jected to Fourier transform infrared (FTIR, IRAffinity-1, 
Shimadzu   Corporation, Tokyo, Japan) spectroscopy measure-
ment using the potassium bromide (KBr) pellet technique 
in diffuse reflection mode at a resolution of 4 cm−1. The 
nanoparticle powder was mixed with KBr and exposed to 
an infrared source of 500–4000 cm−1. A similar process was 
used for the FTIR study of D. bulbifera tuber extract before 
and after bioreduction.
Bactericidal activity and in combination
The effects of the silver nanoparticles synthesized using 
D. bulbifera tuber extract, standard antibiotics, and a com-
bination of both were tested against both Gram-positive 
and Gram-negative bacterial strains using the disc diffusion 
method on Muller-Hinton agar plates. A single colony of 
each test strain was grown overnight in liquid Muller-Hinton 
medium on a rotary shaker (200 rpm) at 37°C. The cells 
grown overnight were washed twice in sterile phosphate-
buffered saline and the inocula were prepared by dilution 
with phosphate-buffered saline to a 0.4 McFarland standard 
and applied to plates along with the nanoparticles and stan-
dard antibiotics. For determination of the combined effect, 
discs containing 500 µg of different antibiotics were further 
impregnated with 5 µL of freshly prepared silver nanopar-
ticles at a final concentration of 30 µg/disc. After incubation 
at 37°C for 18 hours, the zones of inhibition were measured. 
The assays were performed in triplicate.
Results
Phytochemical analysis
D. bulbifera is known to be rich in diverse phytochemicals 
like phenolics, flavonoids, carbohydrates, and vitamins that 
might play a significant role in the bioreduction of silver 
nanoparticles. Phytochemical analysis of D. bulbifera tuber 
extract revealed a high level of flavonoid content up to 
4 mg/mL. Similarly, D. bulbifera tuber extract was found 
to be rich in phenolic content. Total reducing sugar was 
also found to be comparatively high (up to 3.41 mg/mL), 
followed by starch. Dioscorea is known to contain a saponin 
known as diosgenin. Table 1 shows the presence of diosgenin 
26 µg/mL in D. bulbifera tuber extract. In addition to other 
  phytochemicals, ascorbic acid and citric acid were detected 
in a range of 0.1–0.3 mg/mL.
synthesis of silver nanoparticles  
and optimization study
Bioreduction of Ag+ to Ag0 mediated by D. bulbifera tuber 
extract was monitored by recording the absorption spectra as 
a function of time. The well known yellowish-brown color of 
silver nanoparticles arises due to excitation of surface plasmon 
vibrations with an absorbance maxima at 450 nm (Figure 1). 
This might play a key role in the bioreduction process. A col-
loidal solution with development of intense brown coloration 
indicated the synthesis of silver nanoparticles, which showed 
a steady increase with time on shaking at 150 rpm and 40°C. 
Table 1 Phytochemical content per mL of Dioscorea bulbifera tuber extract
Sample Phytochemicals (mg/mL)
Total flavonoid  
content
Total phenolic  
content
Starch Total reducing  
sugar
Diosgenin Ascorbic acid Citric acid
DBTe 4 ± 0.12 0.53 ± 0.04 1.08 ± 0.02 3.41 ± 0.15 0.026 ± 0.006 0.17 ± 0.005 0.28 ± 0.01
Note: Values are means ± standard deviation (n = 3).
Abbreviation: DBTe, D. bulbifera tuber extract.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Ultraviolet-visible spectra of the reaction mixture of 
D. bulbifera tuber extract and AgNO3 were recorded at regular 
time intervals (Figure 2). Although there was no significant 
synthesis at t = 0 minutes and t = 30 minutes, the rate of 
synthesis increased at t = 60 minutes at a very rapid rate and 
was completed in 5 hours. The silver nanoparticles formed 
employing D. bulbifera tuber extract were found to be very 
stable, possibly because of the starch present in the extract 
that prevented agglomeration, even after 30 days.
Optimization of the AgNO3 concentration was carried 
out by plotting absorbance at the peak wavelengths of silver 
nanoparticles against time. Variation in the reaction kinetics 
was observed at different concentrations (Figure 3). The rate 
of synthesis was found to be maximum at a concentration 
of 0.7 mM, while the higher concentrations had a com-
paratively low rate of bioreduction, with 0.3 mM showing 
the slowest rate of synthesis. Thus, the optimization study 
showed a significant effect of concentration on the synthesis 
of silver nanoparticles.
We further investigated the role of temperature on the 
reaction rate by varying the temperature from 4°C to 50°C. 
Maximal synthesis of silver nanoparticles was achieved at 
50°C (Figure 4). The reaction was slow at lower tempera-
tures, and no significant difference was found at 4°C, 20°C, 
and 30°C. However, an increase in the reaction rate was 
observed with an increase in temperature.
TeM, hrTeM, and energy dispersive 
spectrometry
The shape and size of the synthesized nanoparticles 
were elucidated with the help of TEM and HRTEM. The 
TEM images confirmed formation of silver nanoparticles 
(Figures 5 and 6). Formation of silver nanotriangles is 
a very rare event. The majority were formed as silver 
nanorods and triangles in the size range of 8–20 nm 
(Figure 5A). HRTEM images clearly show that the nano-
particles were mostly spherical in shape. Nanoparticles 
of larger dimensions (about 75 nm) were observed. TEM 
and HRTEM analysis also occasionally demonstrated 
hexagonal nanoparticles along with the triangles and rods 
Figure  1  solution  of  1  mM  AgNO3 (A)  before  and  (B)  after  bioreduction  by 
Dioscorea bulbifera tuber extract at 40°c.
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Figure 2 Ultraviolet-visible spectra recorded as a function of reaction time of 1 mM AgNO3 solution with Dioscorea bulbifera tuber extract at 40°c.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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(Figures 5C and 6D). The silver nanoparticles were aniso-
tropic and included triangular, spherical, and ellipsoidal 
particles (Figure 5D, E, and F). The phytochemicals pres-
ent in the tuber were believed to be the agents responsible 
for reducing the Ag+ to Ag0, but the shape is believed to be 
controlled by chemical factors like ascorbic acid and citric 
acid. Similarly, the starch content of D. bulbifera tuber 
extract may play a vital role in capping. Many triangular-
shaped nanoparticles were observed in addition to the rods. 
Energy dispersive x-ray spectroscopy results confirmed the 
presence of significant amounts of silver with no contami-
nants (Figure 7). The optical absorption peak was observed 
at approximately 3 keV , which is typical for the absorption 
of metallic silver nanocrystallites due to surface plasmon 
resonance. The particle size distribution of the silver nano-
particles determined by dynamic light scattering as shown 
in Figure 8 was found to be about 13.54 nm, which is well 
in agreement with the TEM analysis.
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full width at half the maximum intensity in radians, and θ 
is the Bragg angle. Using the above formula, the calculated 
crystallite size was approximately 10 nm.
FTIr analysis
FTIR absorption spectra of D. bulbifera tuber extract 
before and after reduction of silver are shown in Figure 10. 
D. bulbifera tuber extract shows hydroxyl group in alcoholic 
and phenolic compound which is supported by the presence 
of a strong peak at approximately 3300 cm−1. This sharp 
peak representing O–H bond is not seen in D. bulbifera 
tuber extract after bioreduction. This indicates that the poly-
ols are mainly responsible for reduction of Ag+ into silver 
nanoparticles. This may lead to the disappearance of the 
O–H bond. We could observe free hydroxyl groups in the 
FTIR of silver nanoparticles at 3600 cm−1. The absorbance 
bands at 2931 cm−1, 1625 cm−1, 1404 cm−1, and 1143 cm−1 
are associated with the stretch vibrations of alkyl C–C, 
conjugated C–C with a benzene ring, bending of C–O–H 
and C–O stretch in saturated tertiary or secondary highly 
symmetric alcohol in D. bulbifera tuber extract, respectively. 
The presence of peaks at 3749 cm−1 and 1523 cm−1 indicate 
that the silver nanoparticles may be surrounded by amines, 
because the peaks indicate –NH2 symmetric stretching and 
N–O bonds in nitro compounds.
Antimicrobial effects of antibiotics alone 
and combined with nanoparticles
Silver is well known as one of the most universal antimicrobial 
substances. The individual and combined effects of the 
bioreduced silver nanoparticles with 22 different antibiotics 
were investigated against 14 bacterial strains using the disc 
diffusion method. The diameter of the silver nanoparticle 
inhibition zones against different pathogenic cultures were 
observed (Table 2). Silver nanoparticles exhibited maximum 
cytotoxicity against E. coli and Pseudomonas aeruginosa, 
while moderate activity was found for Salmonella typhi 
and Bacillus subtilis. Silver nanoparticles were found to be 
comparatively less active in killing Staphylococcus aureus. 
Combined with the silver nanoparticles, the antibacterial 
activity of the antibiotics showed wide variation, not only 
between groups but also between members of the same 
group (Table 3). When combined with aminoglycosides, 
ie, amikacin and gentamicin, the silver nanoparticles 
showed comparable synergy (a 0.1–2.2-fold increase), and 
kanamycin was found to be superior against P . aeruginosa, 
showing a 4.2-fold enhancement in inhibition when used 
in combination. However, the best synergy was found with 
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Figure 6 characterization of silver nanoparticles formed with 1 mM AgNO3 and 5% 
Dioscorea bulbifera tuber extract at 40°c by high-resolution transmission electron 
microscopy. (A) silver nanoparticles at a resolution of 20 nm, (B and C) spherical 
silver nanoparticles, and (D) hexagonal silver nanoparticles.
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Figure 7 Representative spot energy-dispersive spectrometer profile confirming 
the presence of silver nanoparticles.
X-ray diffraction analysis
The diffraction data for the dry powder were recorded on a 
Brucker x-ray diffractometer using a Cu Kα (1.54 Å) source. 
Phase formation was confirmed from characteristic peaks 
such as (111), (200), (220), and (311). The data matched with 
the standard Joint Committee for Powder Diffraction Set, Card 
040783, confirming a face-centered cubic structure for the silver 
nanoparticles (Figure 9). The lack of any peaks resembling 
metal or metal oxide other than for pure silver in the diffraction 
data confirmed the purity of the synthesized silver nanopar-
ticles. Broadening of the peak indicated a smaller particle size. 
The crystallite size was calculated using Scherrer’s formula:
  d = 0.9λ/βcos
where 0.9 is the shape factor, generally taken for a cubic 
system, λ is the x-ray wavelength, typically 1.54 Å, β is the International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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streptomycin against E. coli, where inhibition increased by 
11.8-fold. Among the β-lactams, the activity of ampicillin 
was enhanced against Klebsiella pneumoniae, Neisseria 
mucosa, and P . aeruginosa, with an appreciable increase 
in activity of 3–4.2-fold. On the other hand, the activity 
of penicillin was found to be enhanced moderately 
against Acinetobacter baumannii, Enterobacter cloacae, 
P . aeruginosa, B. subtilis, and Pseudomonas koreensis, and 
was highest against K. pneumoniae. It is important to note 
that the efficacy of piperacillin in combination with silver 
nanoparticles was selectively enhanced against A. baumannii 
by up to 3.6-fold. Feropenem showed negligible or no synergy 
in combination with silver nanoparticles against any of 
the organisms tested, except for K. pneumoniae. Similarly, 
in the cephalosporin group of antibiotics, synergy was 
observed only for ceftazidime against E. coli. Polymyxin, 
a cyclic peptide antibiotic, showed negligible variation in 
activity whether used alone or in combination with silver 
nanoparticles against all the test pathogens. Even Gram-
negative bacteria like K. pneumoniae, Proteus mirabilis, and 
P . aeruginosa, were found to be inhibited in the presence 
of a combination of vancomycin and silver nanoparticles, 
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Figure 10 Fourier transform infrared absorption spectra of dried Dioscorea bulbifera 
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Ag+ ions at 50°c.
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which otherwise showed a resistant pattern in the presence 
of the antibiotic alone. Erythromycin showed enhanced 
activity of 1.5–3.0-fold against K. pneumoniae, P . mirabilis, 
P . aeruginosa, S. typhi, and A. baumannii in combination 
with silver nanoparticles. Silver nanoparticles increased 
the efficacy of nalidixic acid, a member of the quinolone 
group of antibiotics, against both Gram-positive and Gram-
negative microbes, in particular E. coli and P . koreensis. 
Rifampicin and tetracyclines showed identical activity in the 
presence and absence of silver nanoparticles against most 
of the tested pathogens. The activity of chloramphenicol 
against P . aeruginosa was remarkably enhanced by up to 
4.9-fold in the presence of silver nanoparticles, but moderate 
synergy was observed against the other Gram-positive 
pathogens tested. Combination of silver nanoparticles with 
nitrofurantoin and trimethoprim showed identical selective 
synergistic efficacy against K. pneumoniae.
Discussion
We have successfully demonstrated a rapid and efficient 
route for synthesis of silver nanoparticles using D. bulbifera 
tuber extract. The development of intense yellowish brown 
color owing to the surface plasmon resonance confirmed the 
synthesis of the silver nanoparticles.10 D. bulbifera tuber is 
a rich source of flavonoids and phenolic acid derivatives.36,26 
Flavonoids play a vital role in the reduction process for 
synthesis of nanoparticles.37 Thus, the high flavonoid and 
phenolic content in D. bulbifera tuber extract revealed in the 
phytochemical analysis strongly supports the potential of 
D. bulbifera tuber extract to bioreduce Ag+ to Ag0. Similarly, 
the reducing sugars that are known to play a vital role in 
bioreduction were found to be predominant in D. bulbifera 
tuber extract.38 It is important to note that D. bulbifera 
  contains ascorbic acid and citric acid in notable amounts.39,40 
This is in agreement with the presence of both ascorbic 
and citric acid in D. bulbifera tuber extract in our study 
as well. Widespread use of ascorbic and citric acid in the 
synthesis of silver nanoparticles provides a strong rationale 
for use of D. bulbifera tuber extract in the synthesis and 
shaping of silver nanoparticles.41–43 Diosgenin is reported 
to be a predominant saponin in D. bulbifera39,44 which might 
contribute to the surfactant properties of D. bulbifera tuber 
extract. Plant surfactants are widely used in the synthesis 
of silver nanoparticles.45 Likewise, the significant starch 
content in D. bulbifera tuber extract reflects the capping 
properties of the extract, and starch is widely used in vari-
ous synthetic processes for capping and stabilizing silver 
  nanoparticles.46 Thus, phytochemical studies support the use 
of D. bulbifera tuber extract as a suitable agent to facilitate 
the synthesis of silver nanoparticles. The complete reduc-
tion of Ag+ within 5 hours indicates that synthesis was 
much faster as compared with other plants like Sesuvium 
portulacastrum L that take 24 hours for complete synthe-
sis of silver nanoparticles to occur.47 Optimization studies 
showed that the sharpness of the peak increased with an 
increase in temperature. Most likely, this occurs due to an 
increase in the reaction rate of conversion of metal ions to 
nanoparticles at higher temperatures.48 Recently, different 
plant systems have been used to synthesize spherical and 
irregular silver nanoparticles.47 Although nanospheres dom-
inated the population of the synthesized silver nanoparticles 
as evident from HRTEM and TEM micrographs, in some 
cases anisotropy was observed similar to other reports.49 
Anisotropy among the silver nanoparticles could be related 
to the recent report by Huang et al mentioning that nascent 
silver crystals formed using Cinnamomum camphora leaf 
powder were gradually enclosed by protective molecules, 
which as a result eliminated rapid sintering of smaller 
nanoparticles, resulting in formation of nanotriangles.12 
The spot energy-dispersive spectrometry data confirmed 
the purity of the metallic nanosilver, while the particle size 
was calculated to be approximately 10 nm from the x-ray 
diffraction data.50,51 The FTIR absorption spectra offered 
information regarding chemical changes in the functional 
groups involved in bioreduction.52 D. bulbifera tubers are 
known to contain various bioactive compounds, including 
flavonoids, terpenoids, phenanthrenes, amino acids, protein, 
and glycosides.53–59 It is speculated that the alcohol groups 
are oxidized to carbonyl groups in the course of reduction, 
which supports the suggestion that polyol groups are pri-
marily responsible for the bioreduction process. Thus, the 
water-soluble fractions of D. bulbifera played key roles in 
the bioreduction of the precursors and evolution of shape 
in the nanoparticles.
Silver ion and silver-based compounds are highly toxic 
to micro-organisms, showing a strong biocidal effect against 
microbial species because these are highly reactive species 
with a large surface area.60–63 Silver nanoparticles produced 
using microbes and plant extracts are known to exhibit potent 
antimicrobial activity.47 Antimicrobial activity determined 
using the disc diffusion method confirmed that combining 
antibiotics with silver nanoparticles resulted in a greater 
bactericidal effect on the test pathogens than either of the 
antibacterial agents used alone. This experiment provides 
solid evidence of the antibacterial synergy between antibiot-
ics and silver nanoparticles. A very interesting   observation International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Table 2 Zone of inhibition (mm) of different concentrations of silver nanoparticles on the test pathogens by disc diffusion method
AgNPs  
μg/disc
Zone diameter (mm)
Acinetobacter  
baumannii
Enterobacter  
cloacae
Escherichia  
coli
Haemophilus  
influenzae
Klebsiella  
pneumoniae
Neisseria  
mucosa
Proteus  
mirabilis
Pseudomonas  
aeruginosa
Salmonella  
typhi
Serratia  
odorifera
Vibrio  
parahaemolyticus
Bacillus  
subtilis
Paenibacillus  
koreensis
Staphylococcus   
aureus
1000 13 12 18 12 16 21 NI 10 12 10 12 17 12 8
500 12 10 15 11 15 20 NI 9 11 9 11 16 11 7
300 11 8 14 9 14 18 NI 8 10 8 9 15 9 NI
100 10 NI 13 8 12 16 NI NI 9 NI 8 13 8 NI
50 8 NI 12 NI 11 15 NI NI NI NI NI 11 NI NI
30 NI NI 10 NI 9 14 NI NI NI NI NI 10 NI NI
20 NI NI 9 NI 8 12 NI NI NI NI NI 9 NI NI
10 NI NI NI NI NI 10 NI NI NI NI NI NI NI NI
Note: All experiments were performed in triplicate, and standard deviations were negligible.
Abbreviations: NI, no inhibition; AgNPs, silver nanoparticles.
Table 3 Zone of inhibition (mm) of different antibiotics against test strains in absence and in presence of silver nanoparticles   
(30 µg/disc)
Antiboitics Acinetobacter  
baumannii
Enterobacter  
cloacae
Escherichia  
coli
Haemophilus  
influenzae
Klebsiella  
pneumoniae
Neisseria  
mucosa
Proteus  
mirabilis
Pseudomonas  
aeruginosa
Salmonella  
typhi
Serratia  
odorifera
Vibrio  
parahaemolyticus
Bacillus  
subtilis
Paenibacillus  
koreensis
Staphylococcus  
aureus
A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C
Aminoglycosides
Amikacin 23.0 23.0 0.0 19.0 20.0 0.1 10.0 18.0 2.2 23.0 23.0 0.0 17.0 17.0 0.0 20.0 26.0 0.7 17.0 17.0 0.0 14.0 22.0 1.5 7.0 8.0 0.3 20.0 20.0 0.0 24.0 24.0 0.0 20.0 20.0 0.0 15.0 20.0 0.8 11.0 15.0 0.9
Gentamycin 13.0 14.0 0.2 17.0 17.0 0.0 17.0 17.0 0.0 23.0 23.0 0.0 18.0 18.0 0.0 30.0 42.0 1.0 20.0 20.0 0.0 27.0 27.0 0.0 7.0 9.0 0.7 26.0 26.0 0.0 30.0 30.0 0.0 20.0 20.0 0.0 20.0 22.0 0.2 17.0 17.0 0.0
Kanamycin 7.0 10.0 1.0 18.0 18.0 0.0 14.0 16.0 0.3 22.0 22.0 0.0 7.0 9.0 0.7 26.0 26.0 0.0 17.0 17.0 0.0 7.0 16.0 4.2 7.0 10.0 1.0 26.0 26.0 0.0 22.0 23.0 0.1 23.0 23.0 0.0 20.0 22.0 0.2 16.0 17.0 0.1
streptomycin 16.0 16.0 0.0 23.0 23.0 0.0 7.0 25.0 11.8 24.0 24.0 0.0 22.0 22.0 0.0 28.0 28.0 0.0 20.0 20.0 0.0 24.0 32.0 0.8 7.0 10.0 1.0 23.0 23.0 0.0 30.0 30.0 0.0 26.0 37.0 0.1 23.0 23.0 0.0 16.0 18.0 0.3
β-Lactams
Amoxicillin 7.0 9.0 0.7 7.0 8.0 0.3 12.0 12.0 0.0 10.0 10.0 0.0 7.0 10.0 1.0 40.0 40.0 0.0 16.0 16.0 0.0 7.0 12.0 1.9 7.0 12.0 1.9 20.0 20.0 0.0 11.0 11.0 0.0 10.0 10.0 0.0 7.0 10.0 1.0 7.0 10.0 1.0
Ampicillin 7.0 12.0 1.9 14.0 14.0 0.0 29.0 29.0 0.0 10.0 10.0 0.0 7.0 15.0 3.6 22.0 50.0 4.2 7.0 7.0 0.0 8.0 16.0 3.0 20.0 27.0 0.8 27.0 27.0 0.0 13.0  14.0 0.2 20.0 34.0 1.9 11.0 13.0 0.4 18.0 19.0 0.1
Penicillin 7.0 13.0 2.4 7.0 12.0 1.9 10.0 10.0 0.0 13.0 13.0 0.0 7.0 16.0 4.2 46.0 48.0 0.1 14.0 14.0 0.0 7.0 13.0 2.4 18.0 24.0 0.8 20.0 20.0 0.0 15.0 15.0 0.0 7.0 11.0 1.5 7.0 11.0 1.5 15.0 15.0 0.0
Piperacillin 7.0 15.0 3.6 18.0 0.0 15.0 15.0 15.0 0.0 17.0 17.0 0.0 18.0 18.0 0.0 40.0 40.0 0.0 18.0 18.0 0.0 26.0 26.0 0.0 15.0 18.0 0.4 24.0 24.0 0.0 20.0 20.0 0.0 10.0 14.0 1.0 7.0 15.0 1.3 15.0 15.0 0.0
Carbapenem
Feropenem 17.0 17.0 0.0 13.0 13.0 0.0 18.0 18.0 0.0 25.0 25.0 0.0 7.0 15.0 3.6 48.0 48.0 0.0 15.0 15.0 0.0 12.0 13.0 0.0 14.0 14.0 0.0 25.0 25.0 0.0 30.0 30.0 0.0 34.0 34.0 0.0 22.0 23.0 0.1 18.0 18.0 0.0
Cephalosporin
ceftazidime 8.0 8.0 0.0 20.0 20.0 0.0 9.0 18.0 3.0 17.0 17.0 0.0 9.0 9.0 0.0 32.0 32.0 0.0 20.0 20.0 0.0 20.0 20.0 0.0 16.0 16.0 0.0 24.0 25.0 0.1 20.0 20.0 0.0 21.0 21.0 0.0 16.0 17.0 0.1 12.0 150 0.6
ceftriaxone 11.0 11.0 0.0 20.0 20.0 0.0 7.0 7.0 0.0 13.0 15.0 0.3 16.0 16.0 0.0 47.0 47.0 0.0 18.0 18.0 0.0 18.5 18.5 0.0 15.0 18.0 0.4 24.0 24.0 0.0 15.0 18.0 0.4 14.0 14.0 0.0 15.0 15.0 0.0 17.0 17.0 0.0
cefotaxime 10.0 130 0.7 23.0 23.0 0.0 7.0 7.0 0.0 14.0 17.0 0.5 16.0 16.0 0.0 30.0 30.0 0.0 15.0 15.0 0.0 15.0 15.0 0.0 18.0 20.0 0.2 25.0 25.0 0.0 16.0 18.0 0.3 15.0 16.0 0.1 18.0 18..0 0.0 20.0 20.0 0.0
Cyclic peptide
Polymyxin 15.0 15.0 0.0 13.0 13.0 0.0 7.0 8.0 0.3 10.0 10.0 0.0 16.0 16.0 0.0 16.0 18.0 0.3 7.0 7.0 0.0 14.0 14.0 0.0 7.0 8.0 0.3 14.0 14.0 0.0 11.0 14.0 0.6 7.0 9.0 0.7 11.0 12.0 0.2 7.0 8.0 0.3
Glycopeptides
Vancomycin 12.0 12.0 0.0 7.0 7.0 0.0 18.0 19.0 0.1 23.0 23.0 0.0 7.0 13.0 2.4 24.0 25.0 0.1 7.0 12.0 1.9 7.0 16.0 4.2 18.0 22.0 0.5 7.0 8.0 0.3 23.0 23.0 0.0 24.0 25.0 0.0 18.0 18.0 0.0 15.0 15.0 0.0
Macrolide
erythromycin 7.0 14.0 3.0 7.0 8.0 0.3 7.0 8.0 0.3 18.0 18.0 0.0 7.0 11.0 1.5 25.0 27.0 0.2 7.0 11.0 1.5 7.0 13.0 2.4 7.0 13.0 2.4 7.0 8.0 0.3 20.0 20.0 0.0 19.0 19.0 0.0 16.0 20.0 0.6 7.0 8.0 0.3
Quinolones
Nalidixic acid 7.0 10.0 1.0 11.0 12.0 0.2 7.0 140 3.0 8.0 8.0 0.0 7.0 7.0 0.0 14.0 14.0 0.0 7.0 9.0 0.7 7.0 13.0 2.4 8.0 10.0 0.6 9.0 14.0 1.4 11.0 12.0 0.2 9.0 12.0 0.8 7.0 13.0 2.4 7.0 11.0 1.5
Rifamycin
rifampicin 20.0 20.0 0.0 13.0 13.0 0.0 15.0 15.0. 0.0. 16.0 16.0 0.0 10.0 15.3 1.3 44.0 44.0 0.0. 15.0 15.0 0.0 15.0 15.0 0.0 21.0 21.0 0.0 13.0 13.0 0.0 18.0 18.0 0.0 16.0 16.0 0.0 17.0 17.0 0.0 7.0 7.0 0.0
Tetracycline
Tetracycline 17.0 17.0 0.0 21.0 21.0 0.0 27.0 27.0 0.0 25.0 25.0 0.0 18.0 18.0 0.0 34.0 38.0 0.2 18.0 18.0 0.0 19.0 20.0 0.1 17.0 20.0 0.4 21.0 22.0 0.1 25.0 25.0 0.0 30.0 39.0 0.7 22.0 24.0 0.2 25.0 25.0 0.0
Doxycycline 21.0 21.0 0.0 18.0 18.0 0.0 12.0 12.0 0.0 24.0 24.0 0.0 13.0 13.0 0.0 34.0 34.0 0.0 10.0 10.0 0.0 11.0 12.0 0.2 21.0 21.0 0.0 20.0 20.0 0.0 28.0 28.0 0.0 19.0 19.0 0.0 19.0 20.0 0.1 11.0 11.0 0.0
Others
chloramphenicol 10.0 10.0 0.0 22.0 22.0 0.0 26.0 26.0 0.0 17.0 17.0 0.0 7.0 12.0 1.9 32.0 32.0 0.0 16.0 16.0 0.0 7.0 17.0 4.9 22.0 24.0 0.2 22.0 22.0 0.0 21.0 21.0 0.0 24.0 32.0 0.8 23.0 25.0 0.2 7.0 10.0 1.0
Nitrofurantoin 7.0 11.0 1.5 9.0 9.0 0.0 8.0 8.0 0.0 10.0 12.0 0.4 7.0 16.0 4.2 8.0 31.0 14.0 9.0 9.0 0.0 7.0 11.0 1.5 7.0 9.0 0.7 7.0 8.0 0.3 13.0 19.0 1.1 11.0 20.0 2.3 7.0 13.0 2.4 7.0 7.0 0.0
Trimethoprim 7.0 11.0 1.5 16.0 16.0 0.0 16.0 170 0.1 7.0 13.0 2.4 7.0 16.0 4.2 25.0 26.0 0.1 7.0 7.0 0.0 7.0 11.0 1.5 7.0 7.0 0.0 7.0 13.0 2.4 7.0 15.0 3.6 7.0 20.0 7.2 7.0 13.0 2.4 7.0 10.0 1.0
Notes: All experiments were done in triplicate, and standard deviations were negligible. Fold increases (C) for different antibiotics against five bacterial pathogens were 
calculated as (B2 − A2)/A2, where A and B are the inhibition zones in mm for antibiotic only and antibiotic in combination with silver nanoparticles, respectively. In the absence 
of bacterial growth inhibition zones, the disk diameters (7 mm) were used to calculate the fold increase (c).
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Table 2 Zone of inhibition (mm) of different concentrations of silver nanoparticles on the test pathogens by disc diffusion method
AgNPs  
μg/disc
Zone diameter (mm)
Acinetobacter  
baumannii
Enterobacter  
cloacae
Escherichia  
coli
Haemophilus  
influenzae
Klebsiella  
pneumoniae
Neisseria  
mucosa
Proteus  
mirabilis
Pseudomonas  
aeruginosa
Salmonella  
typhi
Serratia  
odorifera
Vibrio  
parahaemolyticus
Bacillus  
subtilis
Paenibacillus  
koreensis
Staphylococcus   
aureus
1000 13 12 18 12 16 21 NI 10 12 10 12 17 12 8
500 12 10 15 11 15 20 NI 9 11 9 11 16 11 7
300 11 8 14 9 14 18 NI 8 10 8 9 15 9 NI
100 10 NI 13 8 12 16 NI NI 9 NI 8 13 8 NI
50 8 NI 12 NI 11 15 NI NI NI NI NI 11 NI NI
30 NI NI 10 NI 9 14 NI NI NI NI NI 10 NI NI
20 NI NI 9 NI 8 12 NI NI NI NI NI 9 NI NI
10 NI NI NI NI NI 10 NI NI NI NI NI NI NI NI
Note: All experiments were performed in triplicate, and standard deviations were negligible.
Abbreviations: NI, no inhibition; AgNPs, silver nanoparticles.
Table 3 Zone of inhibition (mm) of different antibiotics against test strains in absence and in presence of silver nanoparticles   
(30 µg/disc)
Antiboitics Acinetobacter  
baumannii
Enterobacter  
cloacae
Escherichia  
coli
Haemophilus  
influenzae
Klebsiella  
pneumoniae
Neisseria  
mucosa
Proteus  
mirabilis
Pseudomonas  
aeruginosa
Salmonella  
typhi
Serratia  
odorifera
Vibrio  
parahaemolyticus
Bacillus  
subtilis
Paenibacillus  
koreensis
Staphylococcus  
aureus
A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C A B C
Aminoglycosides
Amikacin 23.0 23.0 0.0 19.0 20.0 0.1 10.0 18.0 2.2 23.0 23.0 0.0 17.0 17.0 0.0 20.0 26.0 0.7 17.0 17.0 0.0 14.0 22.0 1.5 7.0 8.0 0.3 20.0 20.0 0.0 24.0 24.0 0.0 20.0 20.0 0.0 15.0 20.0 0.8 11.0 15.0 0.9
Gentamycin 13.0 14.0 0.2 17.0 17.0 0.0 17.0 17.0 0.0 23.0 23.0 0.0 18.0 18.0 0.0 30.0 42.0 1.0 20.0 20.0 0.0 27.0 27.0 0.0 7.0 9.0 0.7 26.0 26.0 0.0 30.0 30.0 0.0 20.0 20.0 0.0 20.0 22.0 0.2 17.0 17.0 0.0
Kanamycin 7.0 10.0 1.0 18.0 18.0 0.0 14.0 16.0 0.3 22.0 22.0 0.0 7.0 9.0 0.7 26.0 26.0 0.0 17.0 17.0 0.0 7.0 16.0 4.2 7.0 10.0 1.0 26.0 26.0 0.0 22.0 23.0 0.1 23.0 23.0 0.0 20.0 22.0 0.2 16.0 17.0 0.1
streptomycin 16.0 16.0 0.0 23.0 23.0 0.0 7.0 25.0 11.8 24.0 24.0 0.0 22.0 22.0 0.0 28.0 28.0 0.0 20.0 20.0 0.0 24.0 32.0 0.8 7.0 10.0 1.0 23.0 23.0 0.0 30.0 30.0 0.0 26.0 37.0 0.1 23.0 23.0 0.0 16.0 18.0 0.3
β-Lactams
Amoxicillin 7.0 9.0 0.7 7.0 8.0 0.3 12.0 12.0 0.0 10.0 10.0 0.0 7.0 10.0 1.0 40.0 40.0 0.0 16.0 16.0 0.0 7.0 12.0 1.9 7.0 12.0 1.9 20.0 20.0 0.0 11.0 11.0 0.0 10.0 10.0 0.0 7.0 10.0 1.0 7.0 10.0 1.0
Ampicillin 7.0 12.0 1.9 14.0 14.0 0.0 29.0 29.0 0.0 10.0 10.0 0.0 7.0 15.0 3.6 22.0 50.0 4.2 7.0 7.0 0.0 8.0 16.0 3.0 20.0 27.0 0.8 27.0 27.0 0.0 13.0  14.0 0.2 20.0 34.0 1.9 11.0 13.0 0.4 18.0 19.0 0.1
Penicillin 7.0 13.0 2.4 7.0 12.0 1.9 10.0 10.0 0.0 13.0 13.0 0.0 7.0 16.0 4.2 46.0 48.0 0.1 14.0 14.0 0.0 7.0 13.0 2.4 18.0 24.0 0.8 20.0 20.0 0.0 15.0 15.0 0.0 7.0 11.0 1.5 7.0 11.0 1.5 15.0 15.0 0.0
Piperacillin 7.0 15.0 3.6 18.0 0.0 15.0 15.0 15.0 0.0 17.0 17.0 0.0 18.0 18.0 0.0 40.0 40.0 0.0 18.0 18.0 0.0 26.0 26.0 0.0 15.0 18.0 0.4 24.0 24.0 0.0 20.0 20.0 0.0 10.0 14.0 1.0 7.0 15.0 1.3 15.0 15.0 0.0
Carbapenem
Feropenem 17.0 17.0 0.0 13.0 13.0 0.0 18.0 18.0 0.0 25.0 25.0 0.0 7.0 15.0 3.6 48.0 48.0 0.0 15.0 15.0 0.0 12.0 13.0 0.0 14.0 14.0 0.0 25.0 25.0 0.0 30.0 30.0 0.0 34.0 34.0 0.0 22.0 23.0 0.1 18.0 18.0 0.0
Cephalosporin
ceftazidime 8.0 8.0 0.0 20.0 20.0 0.0 9.0 18.0 3.0 17.0 17.0 0.0 9.0 9.0 0.0 32.0 32.0 0.0 20.0 20.0 0.0 20.0 20.0 0.0 16.0 16.0 0.0 24.0 25.0 0.1 20.0 20.0 0.0 21.0 21.0 0.0 16.0 17.0 0.1 12.0 150 0.6
ceftriaxone 11.0 11.0 0.0 20.0 20.0 0.0 7.0 7.0 0.0 13.0 15.0 0.3 16.0 16.0 0.0 47.0 47.0 0.0 18.0 18.0 0.0 18.5 18.5 0.0 15.0 18.0 0.4 24.0 24.0 0.0 15.0 18.0 0.4 14.0 14.0 0.0 15.0 15.0 0.0 17.0 17.0 0.0
cefotaxime 10.0 130 0.7 23.0 23.0 0.0 7.0 7.0 0.0 14.0 17.0 0.5 16.0 16.0 0.0 30.0 30.0 0.0 15.0 15.0 0.0 15.0 15.0 0.0 18.0 20.0 0.2 25.0 25.0 0.0 16.0 18.0 0.3 15.0 16.0 0.1 18.0 18..0 0.0 20.0 20.0 0.0
Cyclic peptide
Polymyxin 15.0 15.0 0.0 13.0 13.0 0.0 7.0 8.0 0.3 10.0 10.0 0.0 16.0 16.0 0.0 16.0 18.0 0.3 7.0 7.0 0.0 14.0 14.0 0.0 7.0 8.0 0.3 14.0 14.0 0.0 11.0 14.0 0.6 7.0 9.0 0.7 11.0 12.0 0.2 7.0 8.0 0.3
Glycopeptides
Vancomycin 12.0 12.0 0.0 7.0 7.0 0.0 18.0 19.0 0.1 23.0 23.0 0.0 7.0 13.0 2.4 24.0 25.0 0.1 7.0 12.0 1.9 7.0 16.0 4.2 18.0 22.0 0.5 7.0 8.0 0.3 23.0 23.0 0.0 24.0 25.0 0.0 18.0 18.0 0.0 15.0 15.0 0.0
Macrolide
erythromycin 7.0 14.0 3.0 7.0 8.0 0.3 7.0 8.0 0.3 18.0 18.0 0.0 7.0 11.0 1.5 25.0 27.0 0.2 7.0 11.0 1.5 7.0 13.0 2.4 7.0 13.0 2.4 7.0 8.0 0.3 20.0 20.0 0.0 19.0 19.0 0.0 16.0 20.0 0.6 7.0 8.0 0.3
Quinolones
Nalidixic acid 7.0 10.0 1.0 11.0 12.0 0.2 7.0 140 3.0 8.0 8.0 0.0 7.0 7.0 0.0 14.0 14.0 0.0 7.0 9.0 0.7 7.0 13.0 2.4 8.0 10.0 0.6 9.0 14.0 1.4 11.0 12.0 0.2 9.0 12.0 0.8 7.0 13.0 2.4 7.0 11.0 1.5
Rifamycin
rifampicin 20.0 20.0 0.0 13.0 13.0 0.0 15.0 15.0. 0.0. 16.0 16.0 0.0 10.0 15.3 1.3 44.0 44.0 0.0. 15.0 15.0 0.0 15.0 15.0 0.0 21.0 21.0 0.0 13.0 13.0 0.0 18.0 18.0 0.0 16.0 16.0 0.0 17.0 17.0 0.0 7.0 7.0 0.0
Tetracycline
Tetracycline 17.0 17.0 0.0 21.0 21.0 0.0 27.0 27.0 0.0 25.0 25.0 0.0 18.0 18.0 0.0 34.0 38.0 0.2 18.0 18.0 0.0 19.0 20.0 0.1 17.0 20.0 0.4 21.0 22.0 0.1 25.0 25.0 0.0 30.0 39.0 0.7 22.0 24.0 0.2 25.0 25.0 0.0
Doxycycline 21.0 21.0 0.0 18.0 18.0 0.0 12.0 12.0 0.0 24.0 24.0 0.0 13.0 13.0 0.0 34.0 34.0 0.0 10.0 10.0 0.0 11.0 12.0 0.2 21.0 21.0 0.0 20.0 20.0 0.0 28.0 28.0 0.0 19.0 19.0 0.0 19.0 20.0 0.1 11.0 11.0 0.0
Others
chloramphenicol 10.0 10.0 0.0 22.0 22.0 0.0 26.0 26.0 0.0 17.0 17.0 0.0 7.0 12.0 1.9 32.0 32.0 0.0 16.0 16.0 0.0 7.0 17.0 4.9 22.0 24.0 0.2 22.0 22.0 0.0 21.0 21.0 0.0 24.0 32.0 0.8 23.0 25.0 0.2 7.0 10.0 1.0
Nitrofurantoin 7.0 11.0 1.5 9.0 9.0 0.0 8.0 8.0 0.0 10.0 12.0 0.4 7.0 16.0 4.2 8.0 31.0 14.0 9.0 9.0 0.0 7.0 11.0 1.5 7.0 9.0 0.7 7.0 8.0 0.3 13.0 19.0 1.1 11.0 20.0 2.3 7.0 13.0 2.4 7.0 7.0 0.0
Trimethoprim 7.0 11.0 1.5 16.0 16.0 0.0 16.0 170 0.1 7.0 13.0 2.4 7.0 16.0 4.2 25.0 26.0 0.1 7.0 7.0 0.0 7.0 11.0 1.5 7.0 7.0 0.0 7.0 13.0 2.4 7.0 15.0 3.6 7.0 20.0 7.2 7.0 13.0 2.4 7.0 10.0 1.0
Notes: All experiments were done in triplicate, and standard deviations were negligible. Fold increases (C) for different antibiotics against five bacterial pathogens were 
calculated as (B2 − A2)/A2, where A and B are the inhibition zones in mm for antibiotic only and antibiotic in combination with silver nanoparticles, respectively. In the absence 
of bacterial growth inhibition zones, the disk diameters (7 mm) were used to calculate the fold increase (c).
Abbreviation: AgNPs, silver nanoparticles.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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that A. baumannii, a nosocomial pathogen resistant to almost 
all known antibiotics and metal salts commonly used in 
medicine, could also be sensitized in the presence of silver 
nanoparticles.64–67 Therefore, this combinational approach 
of antibiotics and silver nanoparticles would provide a 
strategy for effective control of A. baumannii. From the 
results, we can conclude that the antimicrobial effect of 
silver nanoparticles is the key contributor to the synergistic 
effect observed with a combination of silver nanoparticles 
and antibiotics.
Scientists have established the antibacterial mechanism 
of β-lactams, chloramphenicol, aminoglycosides, tetracy-
clines, and glycopeptides.68,69 However, there has not been 
a consistent explanation for the antimicrobial mechanism 
of silver, although application of silver to burn wounds has 
been done for more than a century.70 This can be attributed 
to the fact that silver at low concentrations does not enter 
cells, but is adsorbed onto the bacterial surface just as silver 
tends to adsorb to other surfaces.67 Thus, silver ions resist 
dehydrogenation because respiration occurs across the cell 
membrane in bacteria rather than across the mitochondrial 
membrane as in eukaryotic cells.71 Again, some hypotheses 
indicate that catalytic oxidation of silver ions, with nascent 
oxygen, reacts with bacterial cell membranes, leading to cell 
death. A pronounced antimicrobial effect of antibiotics in 
combination with silver nanoparticles was observed in this 
study. This clearly indicates that enhancement of efficacy 
was due to the synergistic antibacterial action between 
antibiotics and silver nanoparticles. As discussed above, 
silver nanoparticles and antibiotics can kill bacteria with 
a different mechanism. Thus, the synergistic effect can act 
as a very powerful tool against resistant micro-organisms. 
A bonding reaction between antibiotics and silver nanopar-
ticles by chelation ultimately increases the concentration of 
antimicrobial agents at specific points on the cell membrane. 
This may be attributed due to the selective approach of 
silver nanoparticles towards the cell membrane that con-
sists of phospholipids and glycoprotein. Therefore, silver 
nanoparticles facilitate the transport of antibiotics to the cell 
surface acting as a drug carrier. As the silver nanoparticles 
bind to the sulfur-containing proteins of the bacterial cell 
membrane, the permeability of the membrane increases, 
facilitating enhanced infiltration of the antibiotics into the 
cell. More recently, it was shown that silver (I) chelation 
prevents unwinding of DNA. Silver nanoparticles are com-
posed of silver (0) atoms.72 Silver nanoparticles are larger in 
size than silver (I) ions, which makes them react with more 
molecules, leading to more antimicrobial activity.
Conclusion
In an attempt to find natural, environmentally benign, and 
easily available plant-based agents for synthesis of metal 
nanoparticles, we have demonstrated for the first time the 
efficiency of D. bulbifera tuber extract in the rapid syn-
thesis of stable silver nanoparticles possessing a variety 
of fascinating morphologies owing to its diverse groups of 
phytochemicals like phenolics, flavonoids, reducing sugars, 
ascorbic acid, citric acid, and diosgenin. Based on our kinetic 
studies, together with evidence obtained from FTIR, we pro-
pose that the main biomolecules responsible for nanoparticle 
synthesis were polyphenols or flavonoids. The results of our 
study show that the combination of silver nanoparticles and 
antibiotics had synergistic antibacterial efficiency against 
the test microbes, particularly P . aeruginosa, E. coli, and 
A. baumannii. To elucidate the mechanism of this synergistic 
antibacterial effect, more elaborate experimental evidence 
will be required. Overall, this combinational approach of 
antibiotic and silver nanoparticles seems to be one of the best 
strategies for control of antibiotic-resistant micro-organisms 
and hence therapeutic management in infection control.
Acknowledgment
SG acknowledges financial support for this work from the 
Institute of Bioinformatics and Biotechnology, University 
of Pune, India.
Disclosure
The authors report no conflicts of interest in this work.
References
1.  Gittins DI, Bethell D, Schiffrin DJ, Nichols RJ. A nanometre-scale 
electronic switch consisting of a metal cluster and redox-addressable 
groups. Nature. 2000;408(6808):67–69.
2.  Darroudi M, Ahmad MB, Abdullah AH, Ibrahim NA. Green synthesis and 
characterization of gelatin-based and sugar-reduced silver nanoparticles. 
Int J Nanomedicine. 2011;6:569–574.
3.  Wise K, Brasuel M. The current state of engineered   nanomaterials in 
consumer goods and waste streams: the need to develop nanoproperty-
quantifiable sensors for monitoring engineered   nanomaterials. Nanotechnol 
Sci Appl. 2011;4:73–86.
4.  Mukherjee P, Roy M, Mandal BP, et al. Green synthesis of highly 
stabilized nanocrystalline silver particles by a non-pathogenic and agri-
culturally important fungus T. asperellum. Nanotechnology. 2008;19(7): 
075103–075110.
5.  Ai J, Biazar E, Jafarpour M, et al. Nanotoxicology and nanoparticle 
safety in biomedical designs. Int J Nanomedicine. 2011;6:1117–1127.
6.  Sastry M, Ahmad A, Khan MI, Kumar R. Biosynthesis of metal nanopar-
ticles using fungi and actinomycete. Curr Sci. 2003;85(2):162–170.
7.  Shankar SS, Rai A, Ankamwar B, Singh A, Ahmad A, Sastry M. Biological 
synthesis of triangular gold nanoprisms. Nat Mater. 2004;3(7):482–488.
8.  Binupriya AR, Sathishkumar M, Yun SI. Myco-crystallization of silver 
ions to nano-sized particles by live and dead cell filtrates of Aspergillus 
oryzae var viridis and its bactericidal activity towards Staphylococcus 
aureus KCCM 12256. Ind Eng Chem Res. 2010;49(2):852–858.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
495
synthesis of silver nanoparticles by D. bulbifera
  9.  Shankar SS, Rai A, Ahmad A, Sastry M. Controlling the optical 
properties of lemongrass extract synthesized gold nanotriangles and 
potential application in infrared-absorbing optical coatings. Chem 
Mater. 2005;17(3):566–572.
  10.  Shankar SS, Rai A, Ankamwar B, Ahmad A, Sastry M. Rapid 
  synthesis of Au, Ag, and bimetallic Au-core-Ag shell nanoparticles 
using neem (Azadirachta indica) leaf broth. J Colloid Interface Sci. 
2004;275(2):496–502.
  11.  Shankar SS, Ahmad A, Sastry M. Geranium leaf assisted biosynthesis 
of silver nanoparticles. Biotechnol Prog. 2003;19(6):1627–1631.
  12.  Huang J, Li Q, Sun D, et al. Biosynthesis of silver and gold nanopar-
ticles by novel sundried Cinnanonumcamphora leaf. Nanotechnology. 
2007;18(10):105104–105114.
  13.  Elavazhagan T, Arunachalam KD. Memecylon edule leaf extract medi-
ated green synthesis of silver and gold nanoparticles. Int J Nanomedicine. 
2011;6:1265–1278.
  14.  Ankamwar B, Damle C, Ahmad A, Sastry M. Biosynthesis of gold 
and silver nanoparticles using Emblica officinalis fruit extract, their 
phase transfer and transmetallation in an organic solution. J Nanosci 
Nanotechnol. 2005;5(10):1665–1671.
  15.  Panacek A, Kvitek L, Prucek R, et al. Silver colloid nanoparticles: 
  synthesis, characterization, and their antibacterial activity. J Phys Chem B.   
2007;110(33):16248–16253.
  16.  Neu HC. Crisis of antibiotic resistance. Science. 1992;257(5073): 
1064–1073.
  17.  Pitout JDD, Sanders CC, Sanders WE. Antimicrobial resistance with 
focus on β-lactam resistance in Gram-negative bacilli. Am J Med. 1997; 
103(1):51–59.
  18.  Craig WA. Antimicrobial resistance issues of the future. Diagn 
  Microbiol Infect Dis. 1996;25(4):213–217.
  19.  Shakibaie MR, Dhakephalkar PK, Kapadnis BP, Chopade BA. Removal 
of silver from photographic wastewater effluent using Acinetobacter 
baumannii BL54. Can J Microbiol. 1999;45(12):995–1000.
  20.  Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA. 
Incidence and prevalence of nosocomial pathogens in ICU with special 
reference to multiresistant Acinetobacter baumannii harboring multiple 
plasmids. Indian J Med Res. 2008;128(8):178–187.
  21.  Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: 
a case study on E. coli as a model for gram-negative bacteria. J Colloid 
Interface Sci. 2004;275(1):177–182.
  22.  Shi Z, Neoh KG, Kang ET. Surface-grafted viologen for precipita-
tion of silver nanoparticles and their combined bactericidal activities. 
Langmuir. 2004;20(16):6847–6852.
  23.  Choi HJ, Han SW, Lee SJ, Kim K. Structure and thermal behavior of 
a layered silver hydroxyalkanecarboxylate. J Colloid Interface Sci. 
2003;264(2):458–466.
  24.  Sautour M, Mitaine-Offer AC, Lacaille-Dubois MA. The Dioscorea genus: 
a review of bioactive steroid saponins. J Nat Med. 2007;61(2):91–101.
  25.  Gao H, Kuroyanagi M, Wu L, Kawahara N, Yasuno T, Nakamura Y. 
Antitumor-promoting constituents from D. bulbifera L. in JB6 mouse 
epidermal cells. Biol Pharm Bull. 2002;25(9):1241–1243.
  26.  Bhandari MR, Kawabata J. Organic acid, phenolic content and anti-
oxidant activity of wild yam (Dioscorea. spp.) tubers of Nepal. Food 
Chem. 2004;88(2):163–168.
  27.  Ghosh S, Ahire M, Patil S, et al. Antidiabetic activity of Gnidia glauca 
and Dioscorea bulbifera: Potent amylase and glucosidase inhibitors. 
Evid Based Complement Alternat Med. 2011; 2012(2012):929051.
  28.  Ghosh S, Patil S, Ahire M, et al. Synthesis of gold nano-anisotrops 
using Dioscorea bulbifera tuber extract. J Nanomater. 2011:2011.
  29.  Luximon-Ramma A, Bahorun T, Soobrattee MA, Aruoma OI. Antioxidant 
activities of phenolic, proanthocyanidin, and flavonoid components in 
extracts of Cassia fistula. J Agric Food Chem. 2002;50(18):5042–5047.
  30.  Wolfe K, Wu X, Liu RH. Antioxidant activity of apple peels. J Agric 
Food Chem. 2003;51(3):609–614.
  31.  Thayumanavan B, Sadasivam S. Physicochemical basis for the pref-
erential uses of certain rice varieties. Qual Plant Foods Hum Nutr. 
1984;34(4):253–257.
  32.  Miller GL. Use of dinitrosalicylic acid reagent for determination of 
reducing sugar. Anal Chem. 1959;31(3):426–428.
  33.  Slack SC, Mader WJ. Colorimetric assay for diosgenin and related 
compounds. Anal Chem. 1961;33(4):625–627.
  34.  Sadasivam S, Manickam A. Biochemical Methods. 3rd ed. New Delhi, 
India: New Age International; 2008.
  35.  Saffran M, Denstedt OF. A rapid method for the determination of citric 
acid. J Biol Chem. 1948;175:849–855.
  36.  Gao H, Hou B, Kuroyanagi M, Wu L. Constituents from anti-tumor-
promoting active part of Dioscorea bulbifera L. in JB6 mouse epidermal 
cells. Asian J Tradit Med. 2007;2(3):104–109.
  37.  Egorova EM, Revina AA. Synthesis of metallic nanoparticles in reverse 
micelles in the presence of quercetin. Colloids Surf A Physicochem Eng 
Asp. 2000:168(1):87–96.
  38.  Panigrahi S, Kundu S, Ghosh SK, Nath S, Pal T. General method 
of synthesis for metal nanoparticles. J Nanopart Res. 2004;6(4): 
 411–414.
  39.  Behera KK, Sahoo S, Prusti A. Biochemical quantification of diosgenin 
and ascorbic acid from the tubers of different dioscorea species found 
in Orissa. Lib Agric Res Cent J Int. 2010;1(2):123–127.
  40.  Suriyavathana M, Indupriya S. Screening of antioxidant potentials in 
Dioscorea bulbifera. Int J Pharm Life Sci. 2011;2(4):661–664.
  41.  Qin Y, Ji X, Jing J, Liu H, Wu H, Yang W. Size control over   spherical 
silver nanoparticles by ascorbic acid reduction. Colloids Surf A 
  Physicochem Eng Asp. 2010;372(1–3):172–176.
  42.  Lee GP, Bignell LJ, Romeo TC, et al. The citrate-mediated shape 
evolution of transforming photomorphic silver nanoparticles. Chem 
Commun. 2010;46(41):7807–7809.
  43.  Dong X, Ji X, Wu H, Zhao L, Li J, Yang W. Shape control of silver 
  nanoparticles by stepwise citrate reduction. J Phys Chem C. 2009; 
113(16):6573–6576.
  44.  Guclu-Ustundag O, Mazza G. Saponins: properties, applications and 
processing. Crit Rev Food Sci Nutr. 2007;47(3):231–258.
  45.  Nadagouda MN, Hoag G, Collins J, Varma RS. Green synthesis of 
Au nanostructures at room temperature using biodegradable plant 
  surfactants. Cryst Growth Des. 2009;9(11):4979–4983.
  46.  Sharma VK, Yngard RA, Lin Y. Silver nanoparticles: Green synthesis 
and their antimicrobial activities. Adv Colloid Interface Sci. 2009; 
145(1–2):83–96.
  47.  Nabikhan A, Kandasamy K, Raj A, Alikunhi NM. Synthesis of antimi-
crobial silver nanoparticles by callus and leaf extracts from saltmarsh 
plant, Sesuvium portulacastrum L. Colloids Surf B Biointerfaces. 
2010;79(2):488–493.
  48.  Song JY, Kim BS. Rapid biological synthesis of silver nanopar-
ticles using plant leaf extracts. Bioprocess Biosyst Eng. 2009;32(1): 
79–84.
  49.  Sathishkumar M, Sneha K, Yun YS. Immobilization of silver nanopar-
ticles synthesized using Curcuma longa tuber powder and extract on 
cotton cloth for bactericidal activity. Bioresour Technol. 2010;101(20): 
7958–7965.
  50.  Kalimuthu K, Babu RS, Venkataraman D, Bilal M, Gurunathan S. 
Biosynthesis of silver nanocrystals by Bacillus licheniformis. Colloids 
Surf B Biointerfaces. 2008;65(1):150–153.
  51.  Cullity BD, Stock SR. Elements of X-ray Diffraction. 3rd ed. Upper 
Saddle River, NJ: Prentice Hall; 2001.
  52.  Socrates G. Infrared and Raman Characteristic Group Frequencies. 
3rd ed. Chichester (UK): John Wiley & Sons Ltd; 2001.
  53.  Teponno RB, Tapondjou AL, Djoukeng JD, et al. Isolation and NMR 
assignment of a pennogenin glycoside from Dioscorea bulbifera L. var 
sativa. Nat Prod Sci. 2006;12(1):62–66.
  54.  Teponno RB, Tapondjou AL, Gatsing D, et al. Bafoudiosbulbins   
A and B, two anti-salmonellal clerodane diterpenoids from Dioscorea 
bulbifera L. var sativa. Phytochemistry. 2006;67(17):1957–1963.
  55.  Teponno RB, Tapondjou AL, Abou-Mansour E, Stoeckli-Evans H, Tane 
P, Barboni L. Bafoudiosbulbins F and G, further clerodan editerpenoids 
from Dioscorea bulbifera L. var sativa and revised structure of bafou-
diosbulbin B. Phytochemistry. 2008;69(12):2374–2379.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
496
Ghosh et al
  56.  Wij M, Rangaswami S. Chemical constituents of Dioscorea bulbifera 
isolation and structure of a new dihydro phenanthrene 2,4,6,7, tetra-
hydroxy -9,10 dihydro phenanthrene and a new phenanthrene 2,4,5,6 
tetra hydroxy phenanthrene. Indian J Chem. 1978;16:643–644.
  57.  Bhandari MR, Kasai T, Kawabata J. Nutritional evaluation of wild yam 
(Dioscorea spp.) tubers of Nepal. Food Chem. 2003;82(4):619–623.
  58.  Bhandari MR, Kawabata J. Assessment of antinutritional factors and 
bioavailability of calcium and zinc in wild yam (Dioscorea spp.) tubers 
of Nepal. Food Chem. 2004;85(2):281–287.
  59.  Komori T. Glycosides from Dioscorea bulbifera. Toxicon. 1997;35(10): 
1531–1536.
  60.  Paknikar K. Antimicrobial activity of biologically stabilized silver 
nanoparticles. United States Patent US 2007/0218555A1. 2007.
  61.  Dibrov P, Dzioba J, Gosink KK, Hase CC. Chemiosmotic mechanism 
of antimicrobial activity of Ag+ in Vibrio cholera. Antimicrob Agents 
Chemother. 2002;46(8):2668–2670.
  62.  Shahverdi A, Fakhimi A, Shahverdi H, Minaian S. Synthesis and 
effect of silver nanoparticles on the antibacterial activity of   different 
  antibiotics against Staphylococcus aureus and Escherichia coli. 
  Nanomedicine. 2007;3(2):168–171.
  63.  Suvorova E, Klechkovskaya V , Kopeikin V , Buffat P. Stability of Ag 
nanoparticles dispersed in amphiphilic organic matrix. J Cryst Growth. 
2005;275(1–2):e2351–e2356.
  64.  Pour NK, Dusane DH, Dhakephalkar PK, Rokhbakhsh ZF, Zinjarde SS, 
Chopade BA. Biofilm formation by Acinetobacter baumannii strains 
isolated from urinary tract infection and urinary catheters. FEMS 
Immunol Med Microbiol. 2011;62(3):328–338.
  65.  Shakibaie MR, Dhakephalkar PK, Kapadnis BP, Salayaghe G, 
Chopade BA. Plasmid mediated silver and antibiotic resistance in 
Acinetobacter baumannii BL54. Iran J Med Sci. 1998;23(12):30–36.
  66.  Deshpande LM, Kapadnis BP, Chopade BA. Metal resistance in 
Acinetobacter and its relation to β-lactamase production. Bio Metals. 
1993;6(1):55–59.
  67.  Deshpande LM, Chopade BA. Plasmid mediated silver resistance in 
Acinetobacterbaumannii BL54. Bio Metals. 1994;7(1):49–56.
  68.  Vu H, Nikaido H. Role of beta-lactam hydrolysis in the mechanism of 
resistance of a beta-lactamase-constitutive Enterobacter cloacae strain 
to expanded-spectrum beta-lactams. Antimicrob Agents Chemother. 
1985;27(3):393–398.
  69.  Fontana R, Amalfitano G, Rossi L, Satta G. Mechanisms of resistance 
to growth inhibition and killing by β-lactam antibiotics in enterococci. 
Clin Infect Dis. 1992;15(3):486–489.
  70.  Pirnay JP, De Vos D, Cochez C, et al. Molecular epidemiology of 
Pseudomonas aeruginosa colonization in a burn unit: Persistence of 
a multidrug-resistant clone and a silver sulfadiazine-resistant clone.   
J Clin Microbiol. 2003;41(3):1192–1202.
  71.  Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD. Interaction of silver-
nitrate with readily identifiable groups: relationship to the antibacterial 
action of silver ions. Lett Appl Microbiol. 1997;25(4):279–283.
  72.  Batarseh K. Anomaly and correlation of killing in the therapeutic 
properties of silver (I) chelation with glutamic and tartaric acids.   
J Antimicrob Chemother. 2004;54(2):546–548.